证券之星消息，1月21日，生物经济（970038）指数报收于2249.37点，涨0.3%，成交272.77亿元，换手 率2.27%。当日该指数成份股中，上涨的有28家，迪安诊断以5.59%的涨幅领涨，下跌的有22家，康弘药 业以1.78%的跌幅领跌。 生物经济（970038）指数十大成份股详情如下： | 代码 | 名称 | 主力净流入(元) | 主力净占比 游资净流入 (元) | | 游资净占比 散户净流入 (元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 000021 | 深科技 | 1.87亿 ﮯ | 3.06% | -9441.13万 | -1.55% | -9272.83万 | -1.52% | | 300142 | 沃森生物 | 6444.78万 | 8.62% | -3115.26万 | -4.16% | -3329.52万 | -4.45% | | 000930 | 中粮科技 | 5427.62万 | 9.84% | 491.65万 | 4 0.89% | -5919.27万 | -10.73% | | 002 ...

Core Viewpoint - The Biotech Economy Index (970038) experienced a slight decline of 0.15%, closing at 2257.43 points on January 19, with a total trading volume of 28.494 billion yuan and a turnover rate of 2.21% [1] Group 1: Index Performance - On the same day, 23 constituent stocks of the Biotech Economy Index saw an increase, with Deep Technology leading the gainers at a rise of 5.2% [1] - Conversely, 25 stocks declined, with Zhifei Biological leading the losses at a drop of 7.19% [1] Group 2: Capital Flow - The net outflow of main funds from the Biotech Economy Index constituents totaled 0.792 billion yuan, while the net inflow from speculative funds was 0.216 billion yuan [2] - Retail investors contributed a net inflow of 0.576 billion yuan to the index constituents [2]

Core Insights - Covation Biomaterials LLC, a subsidiary of Huafeng Group, will sell its entire stake in Primient Covation LLC to Primient, granting Primient 100% ownership of the world's largest bio-based 1,3-propanediol (Bio-PDO) production business. The transaction is expected to be completed in the first quarter of 2026, pending regulatory approvals [1][2]. Group 1 - Primient Covation LLC was established in 2000 and became the first company to achieve large-scale production of bio-based PDO. It has a production capacity of 77,000 tons per year at its facility in Tennessee, USA, and plans to expand capacity by 33,000 tons by April 2024 [2]. - The brands Zemea® and Susterra® under Primient Covation are recognized for their 100% bio-based properties and are widely used in cosmetics, personal care, textiles, coatings, and functional fluids, serving as core raw materials for Sorona® polymer production [2]. Group 2 - The sale marks a strategic divestment of Huafeng Group's overseas bio-based PDO business, following its acquisition of DuPont's bio-based PDO/PTT business for approximately $240 million in June 2022. This divestment highlights the company's strategic shift to focus on core areas [3]. - After divesting the PDO business, Huafeng will concentrate on the commercialization of the next generation of bio-based polyether glycol (BioPTMEG), which is derived from corn husks and does not compete with food resources. This product can replace traditional petroleum-based polytrimethylene ether glycol and is expected to provide significant carbon reduction benefits in various applications [3]. Group 3 - For Primient, this acquisition is a key move to strengthen its leadership in the bio-manufacturing sector. Primient's CEO emphasized the company's deep understanding of the technical capabilities and growth potential of the business since its inception [4]. - Post-transaction, Primient will continue to supply bio-based PDO to Huafeng through long-term supply agreements, ensuring stable raw material supply for Sorona® polymer production [4].

Group 1 - The Biotech Index (970038) closed at 2322.86 points, up 0.43%, with a total transaction volume of 50.71 billion yuan and a turnover rate of 3.77% [1] - Among the index constituents, 23 stocks rose, with Yingke Medical leading at an 8.37% increase, while 27 stocks fell, with Dabo Medical leading the decline at 3.28% [1] - The top ten constituents of the Biotech Index include major companies such as Mindray Medical, which has a weight of 14.57% and a market capitalization of 251.90 billion yuan, and Yuyue Medical, which has a weight of 3.48% and a market capitalization of 45.51 billion yuan [1] Group 2 - The net outflow of main funds from the Biotech Index constituents totaled 643 million yuan, while retail investors saw a net inflow of 771 million yuan [1] - Detailed fund flow data indicates that Yuyue Medical had a net inflow of 35.6 million yuan from main funds, while it experienced a net outflow of 66.06 million yuan from retail investors [2] - Mindray Medical saw a net inflow of 13.7 million yuan from main funds, with retail investors experiencing a net outflow of 36.97 million yuan [2]

Core Viewpoint - The article emphasizes the significance of the "Five Musts" proposed at the Central Economic Work Conference, which serves as a fundamental guideline for current economic work and aims to enhance China's economic stability and strategic positioning in international competition [1][2]. Summary by Relevant Sections Economic Potential and Policy Framework - The "Five Musts" include fully tapping economic potential, balancing policy support with reform and innovation, ensuring effective regulation, combining investments in physical and human capital, and strengthening internal capabilities to face external challenges [1][2]. - The framework is designed as a closed-loop logic system, with "fully tapping economic potential" as the core goal supported by policy reform, market governance, resource allocation, and risk management [2]. Action Guidelines for Economic Development - The "Five Musts" provide a comprehensive action guide for the beginning of the 14th Five-Year Plan, focusing on solidifying the material foundation for Chinese-style modernization and leveraging the advantages of a vast and internally cyclical economy [3]. - The article highlights the importance of multi-dimensional collaboration to convert economic potential into actual high-quality development outcomes [3]. Key Development Directions - The article identifies three main development directions: boosting consumption and effective investment, integrating technological and industrial innovation, and promoting urban-rural integration and regional coordinated development [4]. - Among these, boosting consumption and effective investment is seen as a critical focus for immediate results, while integrating technological and industrial innovation is expected to provide both short-term breakthroughs and long-term empowerment [4]. Emerging Pillar Industries - The article emphasizes the need to expand new technologies and products in sectors such as intelligent economy, green economy, biological economy, and aerospace economy, which are positioned as emerging pillar industries [5][6]. - This strategic focus aims to cultivate new growth engines that support high-quality development and establish a modern industrial system with global competitiveness [7]. Shift in Industrial Development Strategy - The shift from "cultivating and expanding" to "pillar leading" in the context of emerging industries highlights the importance of scale effects and the ability to drive upgrades across the supply chain [7][8]. - The new approach emphasizes a system-wide perspective on industrial development, integrating technology across various sectors and focusing on high quality and high added value [8].

Core Viewpoint - The Biotech Economy Index (970038) closed at 2312.84 points, reflecting a 0.68% increase with a trading volume of 47.837 billion yuan and a turnover rate of 3.49% [1] Group 1: Index Performance - On the day, 30 constituent stocks of the Biotech Economy Index experienced gains, with Di'an Diagnostics leading the rise at 11.9% [1] - Conversely, 19 stocks declined, with Meihua Medical showing the largest drop at 6.93% [1] Group 2: Capital Flow - The net inflow of main funds into the Biotech Economy Index constituents totaled 274 million yuan, while speculative funds saw a net outflow of 85.3729 million yuan [2] - Retail investors also experienced a net outflow of 188 million yuan [2]

Core Viewpoint - The article emphasizes the "Five Musts" proposed at the Central Economic Work Conference, which serve as fundamental guidelines for economic work under the new circumstances, aiming to consolidate and expand the positive momentum of the economy and gain strategic advantages in international competition [1][2]. Summary by Sections Five Musts - The "Five Musts" include: fully tapping economic potential, balancing policy support with reform and innovation, ensuring both flexibility and regulation, integrating investment in physical and human capital, and honing internal capabilities to face external challenges [1][2]. Systematic Framework - The "Five Musts" form a closed-loop logical system centered on the goal of fully tapping economic potential, supported by policy reform, market governance, resource investment, and risk response, creating a complete action framework [2]. Action Guidelines for Economic Work - The article serves as a specific action guide for economic work at the beginning of the 14th Five-Year Plan, emphasizing a systematic thinking framework that balances domestic and international factors while addressing both short-term and long-term goals [3]. Key Development Directions - The article highlights three key development directions: boosting consumption and effective investment, promoting deep integration of technological and industrial innovation, and facilitating urban-rural integration and regional coordinated development [4]. Emerging Pillar Industries - The article identifies intelligent economy, green economy, biological economy, and aerospace economy as new emerging pillar industries, signaling a strategic focus on cultivating new growth engines that support high-quality development [5][6]. Shift in Industrial Development - The shift from "following and catching up" to "leading and layout" in industrial development is marked by focusing on four high-potential areas, aiming to create globally competitive industrial clusters that inject strong momentum into high-quality economic development during the 14th Five-Year Plan [7].

Group 1 - The core viewpoint emphasizes the necessity of fully tapping into economic potential, combining policy support with reform innovation, ensuring effective governance while allowing market flexibility, integrating investments in both physical and human capital, and honing internal capabilities to face external challenges [1][6][20]. Group 2 - Fully tapping into economic potential is crucial for solidifying the material foundation of Chinese-style modernization, leveraging the country's multiple advantages to foster new growth points and high-quality development [2][3]. - China, as the world's second-largest economy, benefits from a vast market that ensures internal circulation, a robust innovation ecosystem, and a strong industrial supply chain, positioning it as a key player in the global economic landscape [3][4]. - The Chinese economy has shown resilience against external shocks, maintaining its status as a major contributor to global economic growth, supported by a large consumer market and a complete industrial system [4][21]. Group 3 - The approach of combining policy support with reform innovation is essential for addressing the intertwined cyclical, structural, and institutional issues in the economy, ensuring effective macroeconomic governance [7][9]. - This dual approach has been proven effective in navigating complex domestic and international environments, enhancing macroeconomic stability while promoting structural reforms [8][10]. Group 4 - Achieving a balance between market freedom and government regulation is vital for enhancing economic governance and ensuring high-quality development [12][13]. - The focus should be on creating a fair competitive environment while allowing market forces to allocate resources efficiently, thus fostering a dynamic economic order [14][15]. Group 5 - Investments should be closely integrated between physical assets and human capital, with a shift towards enhancing human development as the economy matures [16][18]. - There is significant room for improvement in both physical and human capital investments, with current levels lagging behind developed countries, indicating potential growth areas [17][19]. Group 6 - The emphasis on internal capabilities is crucial for responding to external challenges, with a focus on maintaining strategic determination and leveraging the advantages of a large economy [20][22]. - Historical resilience against external shocks has been demonstrated, with strategies to shift towards domestic demand and innovation driving economic stability and growth [21][23].

Group 1 - The core index of the biotechnology sector, the Biotechnology Index (970038), closed at 2297.26 points, reflecting a 1.74% increase with a trading volume of 34.699 billion yuan and a turnover rate of 2.6% [1] - Among the constituent stocks of the Biotechnology Index, 35 stocks experienced an increase, with Dean Diagnostics leading the rise at 19.98%, while 14 stocks saw a decline, with New Industry leading the drop at 3.84% [1] Group 2 - In terms of capital flow, the Biotechnology Index constituents experienced a net outflow of 190 million yuan from major funds, while retail investors saw a net inflow of 286 million yuan [2] - The detailed capital flow indicates that speculative funds had a net outflow of approximately 95.6729 million yuan [2]

Group 1 - The core index of the biotechnology sector, the Biotechnology Index (970038), closed at 2258.05 points, reflecting a 1.64% increase with a trading volume of 30.954 billion yuan and a turnover rate of 2.47% [1] - Among the constituent stocks of the Biotechnology Index, 40 stocks experienced an increase, with Dean Diagnostics leading the rise at a 20.0% increase, while 10 stocks saw a decline, with Meihao Medical leading the drop at an 11.81% decrease [1] Group 2 - In terms of capital flow, the net inflow of main funds into the Biotechnology Index constituents totaled 110 million yuan, while speculative funds saw a net outflow of 416 million yuan, and retail investors had a net inflow of 306 million yuan [2] - Detailed capital flow information for the constituent stocks is available in the accompanying table [2]